Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients

Netherlands Journal of Medicine

Volumn 69, Issue 11, 2011, Pages 508-513

  Witjes, C D M ^a   Ijzermans, J N M ^a   van der Eijk, A A ^a   Hansen, B E ^a,b   Verhoef, C ^c   de Man, R A ^b  

^a Department of 1Hepatobiliary and Transplantation Surgery ^*  (Netherlands)

^b Gastroenterology and Hepatology   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hbv dna; Hepatitis b virus (hbv); Hepatocellular carcinoma (hcc); Survival; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMIHEPATECTOMY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; VIRUS DETECTION; VIRUS LOAD; WEDGE RESECTION;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SERUM ALBUMIN; SURVIVAL ANALYSIS; VIRAL LOAD; YOUNG ADULT;

EID: 83755225510     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Llovet JM, Burroughs A, Bruix J. H epatocellularc arcinoma. L ancet. 2003;362:1907-17.
2. El-serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-63.
3. Huo TI, Lin HC, Hsia CY, et al. T he m odel fore nd-stage l iver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102:1920-30.
4. Lee W. Hepatitis B virus infection. N Engl Med. 1997;337:1733-45.
5. Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72-S84.
6. Toyama T, Hiramatsu N, Yakushijin T, et al. A new prognostic system for heptocellular carcinoma including recurrent cases a study of 861 patients in a single institution. J Clin Gastroenterol. 2008;42:317-22.
7. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology. 2000;32:1216-23.
8. Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771-80.
9. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at time of resection. Am J Gastroenterol. 2008;103:1663-73.
10. Xu J, Liu L, Tang H. Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: potential to reduce the tumor recurrence rates and/or improve overall survival. Med Hypotheses. 2011;76(3):457-9.
11. Jang JW, Choi JY, Bae SH, et al. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760-7.
12. Huang Y, Wang Z, An S, et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol. 2008;80:591-7.
13. Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000;88:1016-24.
14. Kubo S, Hirohashi K, Tanaka H, et al. Usefulness of viral concentration measurement by transcription-mediated amplification and hybridization protection as a prognostic factor for recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatology Research. 2003;25:71-7.
15. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890-7.
16. Ikeda K, Arase Y, Kobayashi M, et al. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. Intervirology. 2003;46:96-104.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
18. Pas SD, Fries E, de Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol. 2000;38(8):2897-901.
19. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
20. Verhoef C, de Man RA, Zondervan PE, Eijkemans MJ, Tilanus HW, Ijzermans JN. Good outcomes after resection of large hepatocellular carcinoma in the non-cirrhotic liver. Dig Surg. 2004;21:380-6.
21. Trevisani F, D'Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer. 1995;75:2220-32.
22. Van Roey G, Fevery J, van Steenbergen W. Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastoenterol Hepatol. 2000;12:61-6.
23. Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol. 2009;51:842-4.
24. Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44:991-9.
25. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010;53:118-25.
26. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-31.
27. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol. 2010;52:889-94.
28. Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111-20.
29. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
30. Nakai T, Shiraishi O, Kawabe T, Ota H, Nagano H, shiozaki H. Significance of HBV DNA in the hepatic parenchyma from patients with non-B, non-C hepatocellular carcinoma. World J Surg. 2006;30:1338-43.